Janus Kinase Inhibitors: all 1,428 studies that test it

Page 8 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.

• A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of RuxolitinibCompletedNCT01776723Phase 1/2Results posted
• Pacritinib Versus Best Available Therapy to Treat MyelofibrosisTerminatedNCT01773187Phase 3Results posted
• Co-Administration Of Methotrexate And CP-690,550CompletedNCT01745055Phase 1Results posted
• CP-690,550 Thorough QTc StudyCompletedNCT01743677Phase 1Results posted
• Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal FunctionCompletedNCT01740362Phase 1Results posted
• Multiple Dose Escalation Study In Medically Stable Subjects With PsoriasisCompletedNCT01736696Phase 1Results posted
• Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With MyelofibrosisCompletedNCT01732445Phase 2Results posted
• A Study in Moderate to Severe Rheumatoid Arthritis ParticipantsCompletedNCT01721057Phase 3Results posted
• A Moderate to Severe Rheumatoid Arthritis StudyCompletedNCT01721044Phase 3Results posted
• Ruxolitinib for Adult T-Cell LeukemiaTerminatedNCT01712659Phase 1/2Results posted
• A Study in Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT01711359Phase 3Results posted
• A Study in Moderate to Severe Rheumatoid ArthritisCompletedNCT01710358Phase 3Results posted
• Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01710046Phase 2Results posted
• A Study Of CP-690,550 In Stable Kidney Transplant PatientsCompletedNCT01710033Phase 1Results posted
• Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal DiseaseCompletedNCT01710020Phase 1Results posted
• Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)CompletedNCT01693601Phase 1/2Results posted
• A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney DiseaseCompletedNCT01683409Phase 2Results posted
• A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015KCompletedNCT01638013Phase 3Results posted
• Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief StudyCompletedNCT01632904Phase 3Results posted
• Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaTerminatedNCT01620216Phase 2Results posted
• Ruxolitinib in Estrogen Receptor Positive Breast CancerCompletedNCT01594216Phase 2Results posted
• Ruxolitinib in Patients With Breast CancerTerminatedNCT01562873Phase 2Results posted
• Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)CompletedNCT01558739Phase 4Results posted
• A Study of LY3009104 in Healthy ParticipantsCompletedNCT01536951Phase 1Results posted
• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With RuxolitinibTerminatedNCT01523171Phase 2Results posted
• A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic ArthritisCompletedNCT01519089Phase 3Results posted
• Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)CompletedNCT01513902Phase 1Results posted
• Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic ArthritisCompletedNCT01500551Phase 2/3Results posted
• INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.CompletedNCT01493414Phase 3Results posted
• A Phase 2b Study of Baricitinib in Participants With Moderate to Severe PsoriasisCompletedNCT01490632Phase 2Results posted
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative ColitisCompletedNCT01470612Phase 3Results posted
• A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's DiseaseCompletedNCT01470599Phase 2Results posted
• Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate TherapyCompletedNCT01469013Phase 2Results posted
• A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative ColitisCompletedNCT01465763Phase 3Results posted
• A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT01458951Phase 3Results posted
• A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative ColitisCompletedNCT01458574Phase 3Results posted
• Alternative Dosing Strategy of Ruxolitinib in Patients With MyelofibrosisCompletedNCT01445769Phase 2Results posted
• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With MyelofibrosisTerminatedNCT01437787Phase 3Results posted
• SB1518 for Patients With Myelodysplastic Syndrome (MDS)TerminatedNCT01436084Phase 2Results posted
• Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell TransplantCompletedNCT01431209Phase 2Results posted
• Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFCompletedNCT01423851Phase 1/2Results posted
• Study of Ruxolitinib in Pancreatic Cancer PatientsCompletedNCT01423604Phase 2Results posted
• A Relative Bioavailability and Food Effect Study of New FormulationsCompletedNCT01398475Phase 1Results posted
• The Safety And Efficacy Of Maintenance Therapy With CP-690,550CompletedNCT01393899Phase 2Results posted
• A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's DiseaseCompletedNCT01393626Phase 2Results posted
• Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFCompletedNCT01392443Phase 2Results posted
• Ruxolitinib and Lenalidomide for Patients With MyelofibrosisCompletedNCT01375140Phase 2Results posted
• A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or PlaceboCompletedNCT01359150Phase 2Results posted
• Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
• Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsCompletedNCT01340651Phase 2Results posted
• Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)CompletedNCT01317875Phase 1Results posted
• A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01309737Phase 3Results posted
• Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human SubjectsCompletedNCT01299285Phase 1Results posted
• A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01276639Phase 3Results posted
• Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid ArthritisCompletedNCT01262118Phase 1Results posted
• Phase l/II Study of Ruxolitinib for Acute LeukemiaTerminatedNCT01251965Phase 1/2Results posted
• A Study of LY3009104(Baricitinib) for Healthy SubjectsCompletedNCT01247350Phase 1Results posted
• CP-690-550 Ointment For Chronic Plaque PsoriasisCompletedNCT01246583Phase 2Results posted
• Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)CompletedNCT01243944Phase 3Results posted
• A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01241591Phase 3Results posted
• Multiple Ascending Dose of BMS-911543TerminatedNCT01236352Phase 1/2Results posted
• A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque PsoriasisCompletedNCT01186744Phase 3Results posted
• A Study in Participants With Rheumatoid Arthritis on Background Methotrexate TherapyCompletedNCT01185353Phase 2Results posted
• Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)CompletedNCT01164579Phase 2Results posted
• A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque PsoriasisTerminatedNCT01163253Phase 3Results posted
• A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye DiseaseCompletedNCT01135511Phase 2Results posted
• Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTXCompletedNCT01039688Phase 3Results posted
• Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) InhibitorsCompletedNCT00960440Phase 3Results posted
• COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialCompletedNCT00952289Phase 3Results posted
• Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II TrialCompletedNCT00934544Phase 3Results posted
• Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesCompletedNCT00910728Phase 1Results posted
• INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic DrugsCompletedNCT00902486Phase 2Results posted
• A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis MedicationsCompletedNCT00856544Phase 3Results posted
• A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid ArthritisCompletedNCT00853385Phase 3Results posted
• A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background MethotrexateCompletedNCT00847613Phase 3Results posted
• A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque PsoriasisCompletedNCT00820950Phase 2Results posted
• A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid ArthritisCompletedNCT00814307Phase 3Results posted
• A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.CompletedNCT00787202Phase 2Results posted
• A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.CompletedNCT00784719Phase 1/2Results posted
• A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque PsoriasisCompletedNCT00778700Phase 2Results posted
• Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT00726232Phase 2Results posted
• A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With MyelofibrosisCompletedNCT00724334Phase 1/2Results posted
• Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In JapanCompletedNCT00687193Phase 2Results posted
• Topical CP-690,550 For Chronic Plaque PsoriasisCompletedNCT00678561Phase 2Results posted
• Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT00678210Phase 2Results posted
• INCB018424 in Patients With Advanced Hematologic MalignanciesCompletedNCT00674479Phase 2Results posted
• Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In JapanCompletedNCT00661661Phase 3Results posted
• Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant PatientsCompletedNCT00658359Phase 2Results posted
• A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple MyelomaCompletedNCT00639002Phase 2Results posted
• Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate CancerTerminatedNCT00638378Phase 2Results posted
• Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With PsoriasisCompletedNCT00617994Phase 2Results posted
• A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's DiseaseCompletedNCT00615199Phase 2Results posted
• Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in JapanCompletedNCT00603512Phase 2Results posted
• A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid ArthritisCompletedNCT00550446Phase 2Results posted
• A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid ArthritisCompletedNCT00550043Phase 2Results posted
• Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/2Results posted
• Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant PatientsCompletedNCT00483756Phase 2Results posted
• Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid ArthritisCompletedNCT00413699Phase 3Results posted
• Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid ArthritisCompletedNCT00413660Phase 2Results posted
• Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant PatientCompletedNCT00263328Phase 2Results posted

← Janus Kinase Inhibitors overview